

Abstract 118 Table 1

|  |                              | Stroke            | Control           | Difference<br>(95% CI) | p Value |
|--|------------------------------|-------------------|-------------------|------------------------|---------|
| Number of participants                           |                              | 27                | 30                |                        |         |
| Age (years)                                      | Mean                         | 68                | 58                | 10                     | 0.001   |
|  | SD                           | 11                | 11                | 4 to 16                |         |
| Sex  | Male/female                  | 17/27             | 15/15             | 0.13                   | 0.420†  |
|  | Proportion male              | 0.63              | 0.50              | -0.12 to 0.36          |         |
| Height (centimetres)                             | Mean                         | 169.6             | 169.7             | -0.1                   | 0.997   |
|  | SD                           | 7.9               | 12.2              | -5.6 to 5.6            |         |
| O <sub>2</sub> saturations<br>breathing air (%)  | Median                       | 97                | 97                | 0                      | 0.660*  |
|  | IQR                          | 92 to 98          | 95 to 98          | -1 to 1                |         |
| Smoking  | Number ever/<br>never smoked | 13/14             | 12/18             | 0.1                    | 0.599†  |
|  | Proportion ever<br>smoked    | 0.30              | 0.40              | -0.2 to 0.3            |         |
| Functional residual<br>capacity (litres)         | Median                       | 2.500             | 2.780             | -0.270                 | 0.003*  |
|  | IQR                          | 2.323<br>to 3.601 | 2.258<br>to 2.898 | -0.710 to 0.115        |         |
| Functional residual<br>capacity<br>(% predicted) | Median                       | 76.0              | 90.0              | -14.0                  | <0.001* |
|  | IQR                          | 66.5<br>to 89.5   | 79.8<br>to 105.0  | -22.0 to -5.0          |         |
| Peak cough flow rate<br>(litres/min)             | Mean                         | 297               | 380               | -83                    | 0.019   |
|  | SD                           | 133               | 121               | -153 to -14            |         |
| Peak cough flow rate<br>(% predicted PEF)        | Mean                         | 61.2              | 86.3              | -25.1                  | <0.001  |
|  | SD                           | 32.6              | 17.3              | -38.8 to -11.4         |         |
| Volume inspired before<br>cough (litres)         | Mean                         | 2.219             | 3.409             | -1.190                 | <0.001  |
|  | SD                           | 0.828             | 0.720             | -1.715 to 0.665        |         |
| Volume Inspired before<br>cough (% predicted VC) | Mean                         | 64.3              | 94.6              | -30.1                  | <0.001  |
|  | SD                           | 19.5              | 15.6              | -42.2 to 18.5          |         |

p Values calculated using t tests except.

\*p Value calculated using Mann-Whitney U test.

†p Value calculated using Fisher's exact test.

PEF, peak expiratory flow rate; O<sub>2</sub>, oxygen.

## REFERENCE

1. Quanjer PH, et al. *Eur Respir J Suppl* 1993;16:5-40.

## S119 VARIATION IN PHARYNGEAL PH IN THE DIAGNOSIS OF AIRWAY REFLUX

doi:10.1136/thx.2010.150946.20

I D Molyneux, W Jackson, A H Morice. *Castle Hill Hospital, Cottingham, UK*

**Introduction and objectives** Reflux of gastric contents to the laryngopharynx has been implicated in the pathogenesis of chronic cough and may exacerbate other respiratory conditions. Direct measurement of pharyngeal pH is available but standard analysis relies on the pH crossing a lower threshold. Non-acid gaseous reflux may cause respiratory symptoms without producing a significant drop in pharyngeal pH. We theorised that variation in pharyngeal pH might be a useful marker of airway reflux.

**Methods** Measurements of pH in the pharynx over 24 h were made in patients with a variety of respiratory diagnoses suspected to have reflux contributing to their symptoms. Diagnoses included chronic cough, cystic fibrosis and asthma. Results were analysed using a pre-defined, threshold-based scoring system and our novel system based on variation in pH. Comparison was also made with oesophageal physiology where available.

**Results** 60 studies were performed on 58 patients; median age 48 years (range 17-81). 43 studies had an abnormal threshold score. 31 patients had an abnormal variation score (>30 events per hour). Both were positive in 21 patients and both negative in 7. Cough symptom scores were similarly high in patients with abnormal

variation to those with abnormal threshold scores (mean 34.7 and 38.3 respectively) and higher than patients with both negative (23.0; n/s). Cough patients who had undergone fundoplication demonstrated less variation than those who had not (mean events 55 per hour vs 115; n/s). Asthma patients had similar overall variation to other groups but had higher numbers of events over fewer peak hours (468 vs 368 events per peak hour; p=0.08) with the opposite seen in cystic fibrosis patients (276; p=0.26). Of 25 patients with an abnormal pharyngeal study and an oesophageal study available, 15 had normal oesophageal studies.

**Conclusions** These results show that the interaction between pharyngeal pH and airway symptoms is complex, not easily assessed using a pH threshold alone and not well correlated with oesophageal physiology. Assessment of variation suggests different patterns of reflux may relate to disease phenotypes. The ideal analysis should include correlation of clinical symptoms with peaks in variation and pH threshold events.

## Inflammation: an important regulator of the fibrotic response

### S120 IL-1 IS A KEY EPITHELIAL ALARMIN WHICH PROMOTES FIBROBLAST ACTIVATION

doi:10.1136/thx.2010.150946.21

M I Suwara, L A Borthwick, J Mann, A J Fisher, D A Mann. *Newcastle University, Newcastle upon Tyne, UK*

**Background** Alarmins are molecular 'danger signals' released by injured cells that can contribute to the innate immune response by activating immune cells via multiple receptors including Toll-like receptors (TLR), Nod-like receptors (NLR) and the receptor for advanced glycation end products (RAGE). Pulmonary fibrosis is associated with the upregulation of alarmins such as Interleukin 1  $\alpha$  (IL-1 $\alpha$ ) and High mobility group box 1 (HMGB1) in bronchoalveolar lavage fluid (BAL), however it remains unclear whether alarmins can contribute directly to the fibrogenic process by interacting with fibroblasts. We hypothesised that alarmins released from damaged epithelial cells act as damage associated molecular patterns (DAMPs) which are recognised by fibroblasts and lead to their activation.

**Methods** The 16HBE14o- human bronchial epithelial cell line was damaged by hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) induced oxidative stress and alarmin release (Heat Shock Protein 60 (HSP-60), HMGB1, IL-1 $\alpha$ ) measured via ELISA. MRC5 human lung fibroblasts were treated with media from damaged lung epithelia and cell proliferation (XTT proliferation assay), phosphorylation of downstream TLR signalling molecules (interleukin 1 receptor associated kinase 1 (IRAK1), TGF $\beta$  associated kinase 1 (TAK1)—western blotting) and gene expression of proinflammatory cytokines (interleukin 6 (IL-6) and Interferon  $\beta$  (IFN $\beta$ )—qRT-PCR) assessed.

**Results** Conditioned media from 16HBE14o- cells damaged with 200  $\mu$ M H<sub>2</sub>O<sub>2</sub> contained elevated concentrations of HSP-60 (16.7 vs 0.64 ng/ml; p<0.05, n=3), HMGB1 (71 vs 12 ng/ml; p<0.001, n=3) and IL-1 $\alpha$  (434 vs 130 pg/ml; p<0.001, n=3) compared to untreated controls. Treatment of MRC5 cells with media from damaged lung epithelia enhanced cell proliferation by 29% (p<0.01, n=3), increased TAK1 and IRAK1 phosphorylation and increased IL-6 and IFN $\beta$  gene expression 2.7-fold (p<0.001, n=3) and threefold (p<0.001, n=3) respectively. Blocking IL-1R (500 ng/ml of IL-1R antagonist (IL-1Ra)) diminished IL-6 (85%; p<0.01, n=3) and IFN $\beta$  (34%; p<0.05, n=3) gene expression compared to treatment with conditioned media from damaged cells alone.

**Conclusions** The results suggest that alarmins such as the interleukin-1 family, released by damaged human lung epithelia may be